# Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

> **NCT00563810** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 72 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MYO-029

## Key facts

- **NCT ID:** NCT00563810
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 72 (—)
- **Last updated:** 2007-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563810, "Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00563810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*